Literature DB >> 19329017

Severe remifentanil-induced acute opioid tolerance following awake craniotomy in an adolescent.

Paul A Stricker1, F Wickham Kraemer, Arjunan Ganesh.   

Abstract

Anesthetic goals for procedures involving resections close to the motor cortex include immobility, analgesia, and a level of consciousness that allows for the ability to follow motor commands. Remifentanil as a single agent is an attractive choice, particularly when ventilation is controlled. The successful use of large-dose remifentanil infusion during an awake craniotomy in a 16 year-old man and the subsequent severe acute opioid tolerance is presented.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19329017     DOI: 10.1016/j.jclinane.2008.06.032

Source DB:  PubMed          Journal:  J Clin Anesth        ISSN: 0952-8180            Impact factor:   9.452


  4 in total

1.  Effects of remifentanil versus nitrous oxide on postoperative nausea, vomiting, and pain in patients receiving thyroidectomy: Propensity score matching analysis.

Authors:  Min Kyoung Kim; Myung Sub Yi; Hyun Kang; Geun-Joo Choi
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

Review 2.  Designing a pain management protocol for craniotomy: A narrative review and consideration of promising practices.

Authors:  Susana Vacas; Barbara Van de Wiele
Journal:  Surg Neurol Int       Date:  2017-12-06

3.  Remifentanil used as adjuvant in general anesthesia for spinal fusion does not exhibit acute opioid tolerance.

Authors:  Jong Hoon Yeom; Kyoung Hun Kim; Myong-Su Chon; Jangwon Byun; Sang Yun Cho
Journal:  Korean J Anesthesiol       Date:  2012-08-14

4.  Total intravenous anaesthesia with high-dose remifentanil does not aggravate postoperative nausea and vomiting and pain, compared with low-dose remifentanil: a double-blind and randomized trial.

Authors:  Seong-Hyop Kim; Chung-Sik Oh; Tae-Gyoon Yoon; Min Jeng Cho; Jung-Hyun Yang; Hye Ran Yi
Journal:  ScientificWorldJournal       Date:  2014-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.